The higher-dose formulation of semaglutide is indicated as an adjunct to diet and exercise for long-term weight management in adults with obesity (initial body mass index (BMI) 30 kg/m2) or who are overweight (initial BMI 27 kg/m2) and have at least one weight-related comorbidity
EU: Investigation, Writing review and editing
Yes, long-term use is safe according to multi-year clinical trials
We are pleased that the FDA has accepted our submission and look forward to working with regulatory authorities on what would be the first oral GLP-1 treatment for obesity. Novo is advancing other oral drugs for treating obesity
This particular arrangement was first isolated and characterized in 1993 by researchers at the University of Zagreb, Croatia, led by Dr
One study found that 32% of patients receiving IV glutathione experienced adverse events, including liver dysfunction and one case of anaphylaxis.[8] The FDA has issued warnings about contaminated IV glutathione causing hospitalizations.[9] Theres no long-term safety data for ongoing IV use
